FREDUN
Fredun Pharmaceuticals share price & financials
- Price
- ₹970
- Market cap
- ₹2.3k Cr
- Sector
- Healthcare
Quarterly results
Q1 FY27: revenue up 90.0%, net profit up 85.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 107 | 103 | 167 | 120 | 145 +36% | 161 +56% | 213 +28% | 228 +90% |
| EBITDA | 14 | 13 | 17 | 17 | 22 +57% | 26 +100% | 29 +71% | 33 +94% |
| Net profit | 4 | 5 | 7 | 7 | 10 +150% | 10 +100% | 11 +57% | 13 +86% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +12.8% 1Y
1Y: ₹1,251.7 on 10 Sept 2025 → ₹1,412.2. High ₹2,814.3 (30 Jun 2026), low ₹885.75 (22 Jul 2026).
Financials, as filed
Revenue grew 35.3% a year over 2 years, FY24 to FY26. Operating margin widened to 14.7%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹349 Cr | ₹456 Cr | ₹639 Cr |
| Operating profit | ₹40 Cr | ₹54 Cr | ₹94 Cr |
| Operating margin | 11.5% | 11.8% | 14.7% |
| Interest | ₹14 Cr | ₹22 Cr | ₹40 Cr |
| Depreciation | ₹4 Cr | ₹4 Cr | ₹8 Cr |
| Net profit | ₹15 Cr | ₹20 Cr | ₹38 Cr |
| Net margin | 4.3% | 4.4% | 5.9% |
| Cash from operations | ₹0 Cr | ₹-21 Cr | ₹16 Cr |
| Free cash flow | ₹-8 Cr | ₹-27 Cr | ₹-57 Cr |
| ROCE | 17.0% | 19.0% | 21.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| Reserves | ₹39 Cr | ₹64 Cr | ₹92 Cr | ₹117 Cr | ₹153 Cr | ₹273 Cr |
| Borrowings | ₹40 Cr | ₹53 Cr | ₹87 Cr | ₹106 Cr | ₹171 Cr | ₹222 Cr |
| Other liabilities | ₹79 Cr | ₹66 Cr | ₹74 Cr | ₹81 Cr | ₹136 Cr | ₹141 Cr |
| Total liabilities | ₹162 Cr | ₹187 Cr | ₹257 Cr | ₹308 Cr | ₹464 Cr | ₹642 Cr |
| Fixed assets | ₹30 Cr | ₹32 Cr | ₹39 Cr | ₹47 Cr | ₹65 Cr | ₹118 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr |
| Other assets | ₹131 Cr | ₹155 Cr | ₹218 Cr | ₹260 Cr | ₹397 Cr | ₹522 Cr |
| Total assets | ₹162 Cr | ₹187 Cr | ₹257 Cr | ₹308 Cr | ₹464 Cr | ₹642 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jul 2026
Since Jun 2025, promoters trimmed −4.36 pp while the public added +1.94 pp. The shareholder count grew 21% to 9,598.
- Promoters
- 44.6%
- FIIs
- 1.1%
- DIIs
- 2.9%
- Public
- 51.4%
Since Jun 2025
- Promoters −4.36 pp
- Public +1.94 pp
- DIIs +1.35 pp
How it drifted, 12 quarters
Over this window promoters fell from 49.2% to 44.6% — −4.6 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 49.2%, DIIs 1.6%, Public 49.2%.Mar '24: Promoters 49.2%, DIIs 1.6%, Public 49.2%.Jun '24: Promoters 49.2%, DIIs 1.6%, Public 49.2%.Sep '24: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Dec '24: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Mar '25: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Jun '25: Promoters 48.9%, DIIs 1.6%, Public 49.5%.Sep '25: Promoters 48.9%, FIIs 0.0%, DIIs 1.6%, Public 49.5%.Dec '25: Promoters 43.1%, FIIs 0.5%, DIIs 3.5%, Public 53.0%.Mar '26: Promoters 44.2%, FIIs 1.1%, DIIs 2.8%, Public 51.9%.Jun '26: Promoters 44.6%, FIIs 1.1%, DIIs 2.9%, Public 51.5%.Jul '26: Promoters 44.6%, FIIs 1.1%, DIIs 2.9%, Public 51.4%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Nikhil Kishorchandra Vora newly disclosed 5.43% held
- Capri Global Ventures Private Limited newly disclosed 1.45% held
- Arun Kumar Mukherjee newly disclosed 1.24% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jul 2026 filing
Every holder of Fredun Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Daulat Nariman Medhora | 39.37% | unchanged |
| Nikhil Kishorchandra Vora | 5.43% | newly disclosed |
| Fredun Nariman Medhora | 5.19% | unchanged |
| Capri Global Ventures Private Limited | 1.45% | newly disclosed |
| Bank of India Bank | 1.36% | unchanged |
| Arun Kumar Mukherjee | 1.24% | newly disclosed |
| NAV Capital Vcc - NAV Capital Emerging Star Fund FPI fund | 1.02% | unchanged |
| Nariman Bamansha Medhora | 0.01% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹1412, this stock must grow earnings at 8% every year for 7 years. Our analysis caps realistic growth at ~59%. At that growth it is worth ₹16571 — upside of 1073%.
- Growth the price implies
- 7.9% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 59.2% a year
- net profit, FY24–FY26
- The gap
- -0.5 pp
- 1073% downside if it only repeats history
Learn to analyse Fredun Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.